CORMEDIX INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum
CORMEDIX INC. (CRMD) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum of 162.98% for the 6-month period ending 2019-06-30, per its 10-Q filed 2019-08-14.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum · last filed 2019-08-14
- CORMEDIX INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for the quarter ending 2019-03-31 was 110.34%, a 16.64% increase year-over-year.
- CORMEDIX INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for the quarter ending 2018-09-30 was 98.21%, a 1.90% decline year-over-year.
- CORMEDIX INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for the quarter ending 2018-03-31 was 94.60%, a 9.62% decline year-over-year.
- CORMEDIX INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for the quarter ending 2017-09-30 was 100.11%.
- CORMEDIX INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for fiscal 2013 was 131.00%, a 3.15% increase from fiscal 2012.
- CORMEDIX INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for fiscal 2012 was 127.00%, a 10.43% increase from fiscal 2011.
- CORMEDIX INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for fiscal 2011 was 115.00%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum 12 month |
|---|---|---|---|---|
| 2019-06-30 | 162.98% 10-Q · filed 2019-08-14 | |||
| 2019-03-31 | 110.34% 10-Q · filed 2019-05-13 | |||
| 2018-09-30 | 98.21% 10-Q · filed 2018-11-14 | 98.21% 10-Q · filed 2018-11-14 | ||
| 2018-06-30 | 95.51% 10-Q · filed 2018-08-14 | |||
| 2018-03-31 | 94.60% 10-Q · filed 2019-05-13 | |||
| 2017-09-30 | 100.11% 10-Q · filed 2018-11-14 | 105.07% 10-Q · filed 2018-11-14 | ||
| 2017-06-30 | 105.07% 10-Q · filed 2018-08-14 | |||
| 2017-03-31 | 104.67% 10-Q · filed 2018-05-15 | |||
| 2016-09-30 | 98.00% 10-Q · filed 2017-11-09 | |||
| 2016-06-30 | 98.00% 10-Q · filed 2017-08-09 | |||
| 2014-03-31 | 113.00% 10-Q · filed 2014-05-15 | |||
| 2013-12-31 | 131.00% 10-K · filed 2014-03-31 | |||
| 2013-09-30 | 131.00% 10-Q/A · filed 2014-03-04 | |||
| 2013-06-30 | 131.00% 10-Q/A · filed 2014-03-04 | |||
| 2013-03-31 | 131.00% 10-Q · filed 2014-05-15 | |||
| 2012-12-31 | 127.00% 10-K · filed 2014-03-31 | |||
| 2012-09-30 | 115.00% 10-Q/A · filed 2014-03-04 | |||
| 2012-06-30 | 115.00% 10-Q/A · filed 2014-03-04 | |||
| 2012-03-31 | 114.00% 10-Q/A · filed 2014-03-04 | |||
| 2011-12-31 | 115.00% 10-K/A · filed 2014-03-04 | |||
| 2011-09-30 | 115.00% 10-Q/A · filed 2013-03-27 | |||
| 2011-06-30 | 114.00% 10-Q/A · filed 2012-09-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |